AIDS related Kaposi’s sarcoma

Active Ingredient: Alitretinoin

Indication for Alitretinoin

Population group: men, only adults (18 - 65 years old)

Alitretinoin is indicated for the topical treatment of cutaneous lesions in patients with AIDS related Kaposi’s sarcoma (KS) when:

  • lesions are not ulcerated or lymphoedematous
  • treatment of visceral KS is not required
  • lesions are not responding to systemic antiretroviral therapy
  • radiotherapy or chemotherapy are not appropriate

For this indication, competent medicine agencies globally authorize below treatments:

2-4 shifts per day

Route of admnistration

Cutaneous

Defined daily dose

2 - 4 {spreads}

Dosage regimen

From 1 To 2 {spreads} 2 time(s) per day every day for 84 day(s)

Detailed description

Alitretinoin therapy should only be initiated and maintained by specialist physicians experienced in the treatment of patients with KS.

Patients should apply alitretinoin to cutaneous KS lesions using sufficient gel so as to cover each lesion with a generous coating.

Frequency of application Patients should initially apply alitretinoin twice a day to cutaneous KS lesions. The application frequency can be increased stepwise to three or four times a day according to individual lesion tolerance, allowing no less than two weeks between dose increases. The frequency of application should be adjusted for each lesion independently. If application site toxicity occurs, the application frequency can be reduced as described below. There are no data on the efficacy of alitretinoin applied less frequently than twice daily.

Dosage considerations

Patients should wash their hands before and after applications; it is not necessary to wear gloves. The gel must be allowed to dry for three to five minutes before covering with clothing. Occlusive dressings should be avoided.

Care must be taken to avoid application of the gel to normal skin surrounding the lesions.

Gel should not be applied on or near eyes or mucosal surfaces of the body. Showering, bathing, or swimming for at least three hours after any application should be avoided.

Active ingredient

Alitretinoin

Alitretinoin is a naturally-occurring endogenous hormone related to vitamin A, binds to and activates all known intracellular retinoid receptor subtypes (RAR, RAR, RAR, RXR, RXR, RXR). The efficacy of alitretinoin in treating KS lesions may be related to the demonstrated ability of alitretinoin to inhibit the in vitro growth of KS cells.

Read more about Alitretinoin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.